Marimastat in patients with advanced pancreatic cancer. A dose-finding study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 3, 1999, Pages 247-252

  Rosemurgy, Alexander ^a   Harris, Jules ^b   Langleben, Adrian ^c   Casper, Ephraim ^d   Goode, Sara ^a   Rasmussen, Henrik ^e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e British Biotech Inc   (United States)

Author keywords

Advanced pancreas cancer; Cancer specific antigens; Matrix metalloproteinase inhibition; Safety; Tolerability

Indexed keywords

FLUOROURACIL; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PANCREAS CANCER; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0033509553     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199906000-00007     Document Type: Article

References (15)

1. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
2. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-41.
3. Belaaouaj A, Shipley JM, Kobayashi DK, et al. Human macrophage metalloelestase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J Biol Chem 1995;270:14568-75.
4. Okada A, Bellocq JO, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-4.
5. Takino T, Sato H, Shinagawa A, et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library - MT-MMPs from a unique membrane-type subclass in the MMP family. J Biol Chem 1995;270: 23013-20.
6. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
7. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89: 1260-70.
8. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-18.
9. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 1995;6:967-74.
10. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
11. Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998;45: 21-6.
12. Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987;60:2428-31.
13. Yasue M, Sakamoto J, Teramukai S, et al. Prognostic values of preoperative and postoperative CEA and CA 19-9 levels in pancreatic cancer. Pancreas 1994;9:735-40.
14. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine in patients with advanced carcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
15. Burris HA III, Moore ML, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.